(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 April 2009 (16.04.2009)

PCT

(10) International Publication Number
WO 2009/047565 A3

(51) **International Patent Classification**:
A61L 9/20 (2006.01) *A61K 9/16* (2006.01)
A61K 31/495 (2006.01)

(21) **International Application Number**:
PCT/GB2008/050928

(22) **International Filing Date**:
9 October 2008 (09.10.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
60/979,736 12 October 2007 (12.10.2007) US
61/089,118 15 August 2008 (15.08.2008) US

(71) **Applicant** *(for all designated States except MG, US)*: **AstraZeneca AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) **Applicant** *(for MG only)*: **AstraZeneca UK Limited** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BLYTH, John, David** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **DAY, Andrew, John** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB). **LENNON, Kieran, James** [GB/GB]; AstraZeneca, Charter Way, Macclesfield Cheshire SK10 2NA (GB).

(74) **Agent**: **GLOBAL INTELLECTUAL PROERTY**; AstraZeneca AB, S-SE-151 85 Södertälje (SE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) **Date of publication of the international search report**:
26 November 2009

WO 2009/047565 A3

(54) **Title**: ZIBOTENTAN COMPOSITION CONTAINING MANNITOL AND/OR MICROCRYSTALLINE CELLULOSE

(57) **Abstract**: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)- 2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide (*i.e.* zibotentan or ZD4054) with mannitol and/or microcrystalline cellulose is described.